impact factor
logo
 

Diagnosis

 

Anti-Ro52 and/or anti-Ro60 immune reactivity: autoantibody and disease associations


1, 2, 3, 4

 

  1. Institute for Autoimmune Systemic and Neurological Diseases, Athens, Greece. zampelieva@gmail.com
  2. Department of Internal Medicine and Autoimmune Diseases, Euroclinic of Athens, Greece.
  3. Academy of Athens, Athens, Greece.
  4. Department of Internal Medicine and Autoimmune Diseases, Euroclinic of Athens, and Department of Nutrition and Dietetics, Harokopio University, Athens, Greece.

CER12844
2020 Vol.38, N°4 ,Suppl.126
PI 0134, PF 0141
Diagnosis

Free to view
(click on article PDF icon to read the article)

PMID: 32083547 [PubMed]

Received: 08/10/2019
Accepted : 08/01/2020
In Press: 18/02/2020
Published: 23/10/2020

Abstract

OBJECTIVES:
This study aims to characterise the clinical phenotype and autoantibody associations in an autoimmune population positive for anti-Ro52 and/or anti-Ro60 autoantibodies.
METHODS:
The sera of 508 individuals tested for autoantibody presence were found positive for anti-Ro52 and/or anti-Ro60. Medical records were available for 272 of them. Correlations of clinical, laboratory and other autoantibodies as well as disease phenotypes with the presence of anti-Ro52 and/or anti-Ro60 reactivity were examined.
RESULTS:
Combined serum anti-Ro52/anti-Ro60 reactivity was the most frequent one, mostly seen in Sjögren’s syndrome (SS) and systemic lupus erythematosus (SLE) patients. In these patients this reactivity strongly associated with anti-La and/or anti-dsDNA autoantibodies. SS patients with combined anti-Ro52/anti-Ro60 and anti-La reactivity had clinical and/or laboratory risk factors for lymphoma development. Solo anti-Ro52 reactivity was primarily found in idiopathic inflammatory myopathies (IIM), primary biliary cholangitis (PBC), rheumatoid arthritis (RA) and SS patients. Solo anti-Ro52 also associated with anti-Jo1 and anti-M2 autoantibodies and with interstitial lung disease (ILD) in a context of IIM-related lung injury. ILD patients with combined anti-Ro52/anti-Ro-60 reactivity were diagnosed mostly as RA and/or SS. Solo anti-Ro60 reactivity strongly correlated with oral ulcers and co-existed with autoantibodies to Sm and nRNP/Sm.
CONCLUSIONS:
Testing for autoantibodies against both Ro peptides may guide diagnosis, classify clinical manifestations in disease entities and define prognosis in certain autoimmune disorders. A distinct weight could be given to the isolated anti-Ro specificities in the SS classification criteria.

Rheumatology Article

Rheumatology Addendum